Redox proteomics: Understanding oxidative stress in the progression of age-related neurodegenerative disorders

Expert Review of Proteomics

Volumn 5, Issue 2, 2008, Pages 157-160

  Butterfield, D Allan ^a   Sultana, Rukhsana ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MEMBRANE PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; EDITORIAL; HUNTINGTON CHOREA; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEOMICS; REDOX PROTEOMICS;

AGE FACTORS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEOMICS;

EID: 43449106831     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.5.2.157     Document Type: Editorial

References (32)

1. Lippi G, Franchini M, Montagnana M, Guidi GC. Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework. Semin. Thromb. Hemost. 33, 759-770 (2007).
2. Roix J, Misteli T. Genomes, proteomes, and dynamic networks in the cell nucleus. Histochem. Cell Biol. 118, 105-116 (2002).
3. Butterfield DA, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 122, 945-962 (2001).
4. Dalle-Donne I, Scaloni A, Butterfield DA. Redox Proteomics: From Protein Modifications to Cellular Dysfunction And Diseases. Dalle-Donne I, Scaloni A, Butterfield DA (Eds). John Wiley & Sons, Hoboken, NJ , USA (2006).
5. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 43, 658-777 (2007).
6. Sultana R, Boyd-Kimball D, Poon HF et al. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging 27, 1564-1576 (2006).
7. Butterfield DA, Gnjec A, Poon HF et al. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 10, 391-397 (2006).
8. Opii WO, Joshi G, Head E et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol. Aging 29, 51-70 (2008).
9. Castegna A, Aksenov M, Aksenova M et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33, 562-571 (2002).
10. Castegna A, Aksenov M, Thongboonkerd V et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, ?-enolase and heat shock cognate 71. J. Neurochem. 82, 1524-1532 (2002).
11. Poon HF, Calabrese V, Calvani M, Butterfield DA. Proteomics analyses of specific protein oxidation and protein expression in aged rat brain and its modulation by L-acetylcarnitine: insights into the mechanisms of action of this proposed therapeutic agent for CNS disorders associated with oxidative stress. Antioxid. Redox Signal. 8, 381-394 (2006).
12. Sultana R, Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem. Res. 29, 2215-2220 (2004).
13. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice - a model of familial Parkinson's disease. Neurobiol. Dis. 18, 492-498 (2005).
14. Poon HF, Hensley K, Thongboonkerd V et al. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice - a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 39, 453-462 (2005).
15. Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 12, 61-72 (2007).
16. Mosconi L, De Santi S, Li Y et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur. J. Nucl. Med. Mol. Imaging 33, 210-221 (2006).
17. Hunt A, Schonknecht P, Henze M, Seidl U, Haberkorn U, Schroder J. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Res. 155, 147-154 (2007).
18. Butterfield DA, Boyd-Kimball D, Castegna A. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J. Neurochem. 86, 1313-1327 (2003).
19. Perluigi M, Fai Poon H, Hensley K et al. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice - a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 38, 960-968 (2005).
20. Reed T, Perluigi M, Sultana R et al. Redox proteomics identification of 4-hydroxy-2-nonenal-modified proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30, 107-120 (2008).
21. Zhou J, Zhou T, Cao R et al. Evaluation of the application of sodium deoxycholate to proteomic analysis of rat hippocampal plasma membrane. J. Proteome Res. 5, 2547-2553 (2006).
22. Rabilloud T, Luche S, Santoni V, Chevallet M. Detergents and chaotropes for protein solubilization before two-dimensional electrophoresis. Methods Mol. Biol. 355, 111-119 (2007).
23. Molloy MP. Two-dimensional electrophoresis of membrane proteins using immobilized pH gradients. Anal. Biochem. 280, 1-10 (2000).
24. Ruan Y, Wan M. An optimized procedure for solubilization, reduction, and transfer of human breast cancer membrane-enriched fraction by 2-DE. Electrophoresis 28, 3333-3340 (2007).
25. Twine SM, Mykytczuk NC, Petit M et al. Francisella tularensis proteome: low levels of ASB-14 facilitate the visualization of membrane proteins in total protein extracts. J. Proteome Res. 4, 1848-1854 (2005).
26. Zischka H, Gloeckner CJ, Klein C, Willmann S, Swiatek-de Lange M, Ueffing M. Improved mass spectrometric identification of gel-separated hydrophobic membrane proteins after sodium dodecyl sulfate removal by ion-pair extraction. Proteomics 4, 3776-3782 (2004).
27. Matt P, Fu Z, Fu Q, Van Eyk JE. Biomarker discovery: proteome fractionation and separation in biological samples. Physiol. Genomics 33(1), 12-17 (2008).
28. Ferguson PL, Smith RD. Proteome analysis by mass spectrometry. Annu. Rev. Biophys. Biomol. Struct. 32, 399-424 (2003).
29. Haqqani AS, Hutchison JS, Ward R, Stanimirovic DB. Biomarkers and diagnosis; protein biomarkers in serum of pediatric patients with severe traumatic brain injury identified by ICAT-LCMS/MS. J. Neurotrauma 24, 54-74 (2007).
30. Lopez JL. Two-dimensional electrophoresis in proteome expression analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 849, 190-202 (2007).
31. Orchard S Proteomics: from technology development to biomarker applications. Expert Rev. Proteomics 4, 709-710 (2007).
32. Klase ZA, Van Duyne R, Kashanchi F. Identification of potential drug targets using genomics and proteomics: a systems approach. Adv. Pharmacol. 56, 327-368 (2008).